Glenmark gets USFDA nod for potassium chloride tablets

By: | Published: July 27, 2016 11:51 AM

Glenmark Pharmaceuticals has received final approval from the US health regulator for Potassium Chloride Extended Release Tablets, used in treating low levels of potassium in blood.

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq (1500mg)," it said in a BSE filing. (Reuters)“Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq (1500mg),” it said in a BSE filing. (Reuters)

Glenmark Pharmaceuticals has received final approval from the US health regulator for Potassium Chloride Extended Release Tablets, used in treating low levels of potassium in blood.

“Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq (1500mg),” it said in a BSE filing.

The tablet is a generic version of K-Dur extended release tablets of Merck Sharp and Dohme Corp.

As per IMS data, K-Dur achieved annual sales of around USD 283.2 million for the 12 months period ended May 2016.

Company’s current portfolio consists of 117 products authorised for distribution in the US marketplace and 61 ANDA pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading 0.32 per cent up, at Rs 845.80 in the morning trade on BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition